Dr. Reddy's Laboratories (DRL or 'the company') is a pharmaceutical company engaged in manufacturing generics, active pharmaceutical ingredients (APIs), and proprietary products. It primarily operates in India, North America, Europe, Russia and other countries of the former Soviet Union.
The company operates through three segments: global generics, pharmaceutical services and active ingredients (PSAI), and proprietary products.
DRL's global generics segment consists of finished pharmaceutical products that are ready for consumption by the patient. These products are marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).The branded generics portfolio offers products in the therapeutic areas of gastrointestinal, cardiovascular, pain management, oncology, anti-infectives, pediatrics and central nervous system under the brand names of Omez, Ciprolet, Nise, Ketorol, Stamlo, Razo and Cetrine in India, Russia, Venezuela, Romania, South Africa and certain countries of the former Soviet Union. The segment is also engaged in over-the-counter (OTC) drug products business. DRL's biologics business is also a part of the company's global generics segment.
The PSAI segment consists of the company's APIs and intermediates, also known as active pharmaceutical products or bulk drugs, which are the principal ingredients for finished pharmaceutical products. This segment also manufactures and sells APIs and steroids in accordance with the specific customer requirements. In addition, the PSAI segment offers contract research services.
The company's proprietary products segment is engaged in the discovery of new chemical entities (NCEs) and differentiated formulations for subsequent commercialization and out-licensing. It also includes the company's specialty pharmaceuticals business which sells and markets in-licensed and co-developed dermatology products. The NCE's therapeutic areas of focus include metabolic disorders, pain and inflammation.
Scope of the Report
-- About the Company - Historical Details, Current Ownership Structure and basic overview of Dr. Reddy's Laboratories Limited in terms of revenue, net income, and operating income.
-- Financials - Details about Dr. Reddy's Laboratories Limited listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
-- Products / Services - Listing of the company’s entire portfolio along with description of individual products / services providing a clear picture of their target audience.
-- Company SWOT Analysis - Outlines Dr. Reddy's Laboratories Limited’s strengths, weaknesses, and opportunities and threats facing the company.
-- Recent Developments - Showcases Dr. Reddy's Laboratories Limited’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
-- Strategic Evaluation - Provides an overview of Dr. Reddy's Laboratories Limited’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
-- Technology Landscape - Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken buy the company at present along with outlook.
Key Questions Answered
-- What domain does Dr. Reddy's Laboratories Limited operate and what are key points about it?
-- What is the product / service portfolio of Dr. Reddy's Laboratories Limited?
-- How has Dr. Reddy's Laboratories Limited performed financially from the 2013?
-- How does Dr. Reddy's Laboratories Limited rank among its peers in terms of revenue and market share?
-- What are Dr. Reddy's Laboratories Limited strengths and weaknesses and what opportunities and threats does it face?
-- What are Dr. Reddy's Laboratories Limited’s main growth strategies and how successful has the company been at implementing them?
-- What is the in-house technical capability of Dr. Reddy's Laboratories Limited? Where does it procure / outsource it?
Reasons to buy
-- Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
-- Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at very competitive cost
-- 12 hour delivery time fulfilling your urgent requests as per your requirement
-- On-demand customization options that can completely cater to your needs by focusing the report onto given specifics
1. About the Company
1.1 History and Basic Facts
1.2 Ownership Structure and Key Executives
1.3 Head Office
1.4 Other Locations & Subsidiaries
1.5 List of Competitors
1.6 Employee Count & Distribution
2.1 Company Type (Listed / Unlisted)
2.2 Annual Statements
2.3 Key Financial Highlights
2.4 Region-wise Breakdown
3. Product / Services
4. SWOT Analysis
4.1 SWOT Overview
5. Recent Developments
5.1 Mergers & Acquisitions
5.2 Partnerships, Collaborations & Joint Ventures
5.3 New Product Launches
5.4 Business Expansion / Divestment
6. Strategic Evaluation
6.1 Corporate Strategy
6.2 Legal Issues
6.3 Analyst Outlook
7. Technology Landscape
-- 7.1.1 Industry Snapshot
-- 7.1.2 IT Spend
-- 7.1.3 Key Information Technology Trends
-- 7.2.1 IT Overview
-- 7.2.2 Key IT Technologies
-- 7.2.3 Recent IT Initiatives
-- 7.2.4 IT Outsourcing Engagements
-- 7.2.5 Key IT Management
-- 7.2.6 CIO/CTO Profile
-- About Us
-- Contact Us
Fig.1: Company Snapshot
Fig.2: Locations Listing on Map
Table.1: Ownership Structure
Table.2: List of Competitors
Table.3: Annual Statements
Table.4: Key Financial Highlights
Table.5: Region-wise Breakdown
Table.6: Product/Services Overview
Table.7: Mergers & Acquisitions
Table.8: Partnerships, Collaborations & Joint Ventures
Table.9: New Product Launches
Table.10: Business Expansion / Divestment
Table 11: IT Budgets
Table 12: Key IT Management (CIO / CTO)
Table 13: IT Deals undertaken in the past years